RecruitingACTRN12623000740695

We aimed to investigate the effects of bilateral sphenopalatine ganglion blockade (SPGB) on postoperative early complications in septorhinoplasty operations.

Randomized Clinical Trial Doubled Blind Study of Bilateral Sphenopalatine ganglion Blockade in Septorhinoplasty Operations


Sponsor

ERHAN GÖKÇEK

Enrollment

80 participants

Start Date

Jul 3, 2023

Study Type

Interventional

Conditions

Summary

The primary aim of our study was to test the hypothesis that SPG blockade provides more analgesia in the first 24 hours postoperatively than the control group in septorhinoplasty operations. In addition, the secondary aim of our study was to investigate the effects of SPG blockade on the ability to further reduce nausea-vomiting, sore throat, and laryngospasm.


Eligibility

Sex: Both males and femalesMin Age: 18 YearssMax Age: 50 Yearss

Inclusion Criteria1

  • Patients aged 18-50 who will undergo elective septorhinoplasty operations.

Exclusion Criteria1

  • Pregnant, known allergy to any of the study drugs, significant cardiac or renal pathology, regular sedative drug intake, atrioventricular block, myasthenia gravis, uncooperative (due to dementia, mental retardation, etc.) , drug or alcohol addiction, and patients who did not want to participate in the study were excluded.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

Sphenopalatine group (Group S, n=40). It was applied with infiltration anesthesia to both groups by the same otolaryngologist with the Sphenocath device(SphenoCath Applicator; Dolor Technologies, Scot

Sphenopalatine group (Group S, n=40). It was applied with infiltration anesthesia to both groups by the same otolaryngologist with the Sphenocath device(SphenoCath Applicator; Dolor Technologies, Scottsdale, Arizona). SPG blockade was performed by a otolaryngologist blinded to the drug used. Patients in group S were performed bilaterally with 2 mL of 0.025% adrenalin-free intranasal bupivacaine (Marcaine 0.5% vial, Astra-Zeneca, Germany) 15 minutes before the end of the operation. The results were evaluated by an anesthesiologist who was not involved in the study. In the recovery unit after the operation; The pain and analgesic needs of the patients at 0, 2, 6 and 24 hours were evaluated. The presence of laryngospasm and the frequency of nausea and vomiting in the first 24 hours were recorded during the recovery period.


Locations(1)

DIYARBAKIR, Turkey

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12623000740695